Form 4: Morgan Stanley Director Shelley Leibowitz Receives Equity Grant

Sentiment:

Insider Transaction Report


Morgan Stanley Director Shelley B. Leibowitz was granted 2,155.455 restricted stock units, increasing her beneficial ownership in the company.

Summary

  • Shelley B. Leibowitz, a Director at Morgan Stanley (MS), acquired 2,155.455 shares of Common Stock on June 1, 2025.
  • The acquisition was a grant of restricted stock units (RSUs) under the Morgan Stanley Directors' Equity Capital Accumulation Plan, with a reported price of $0 per unit.
  • These restricted stock units are convertible into shares of Common Stock at a 1-to-1 ratio.
  • Following this transaction, Ms. Leibowitz's total beneficial ownership of Morgan Stanley Common Stock increased to 48,613.916 shares.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as a director's increased equity stake, even through a grant, generally aligns their interests with shareholders. It's a routine compensation event, not indicative of significant operational changes or financial performance.

Positives

  • The acquisition of additional shares by a director, even through a grant, aligns the director's interests more closely with those of the shareholders, potentially indicating confidence in the company's long-term performance.
  • The grant is part of a pre-existing equity accumulation plan, suggesting a structured approach to director compensation and retention.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This transaction is a routine insider filing for a major financial institution like Morgan Stanley, reflecting standard compensation practices for board members. Equity grants to directors are common across the financial services industry to incentivize long-term alignment with shareholder value.

Comparison to Industry Standards

  • The grant of restricted stock units to directors is a common practice in the financial services industry and aligns with compensation structures seen at comparable firms such as Goldman Sachs (GS), JPMorgan Chase (JPM), and Bank of America (BAC), which also utilize equity-based compensation to incentivize their board members and executives.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Compensation Policy ImplementationThe grant of restricted stock units to Director Shelley B. Leibowitz was made under the Morgan Stanley Directors' Equity Capital Accumulation Plan, indicating the ongoing implementation of the company's established director compensation policy.06/01/2025This reinforces the existing corporate governance framework for director compensation, aiming to align director incentives with long-term shareholder value through equity ownership.

Related Party Transactions

  • The acquisition of 2,155.455 restricted stock units by Director Shelley B. Leibowitz from Morgan Stanley constitutes a related party transaction, as it involves the company and one of its directors as part of a compensation plan.

Stakeholder Impact

  • Shareholders: The transaction increases the director's alignment with shareholder interests through increased equity ownership.
  • Employees: No direct impact on general employees is indicated by this filing.

Key Dates

DateDescription
06/01/2025Date of transaction (acquisition of restricted stock units).
06/03/2025Date the Form 4 was signed by the attorney-in-fact.

Keywords

Morgan Stanley, MS, Shelley B. Leibowitz, Director, Form 4, Insider Transaction, Restricted Stock Units, Equity Grant, Beneficial Ownership, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.